ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 0985

Early and Sustained Reduction in Severity of Skin Disease with Anifrolumab Treatment in Patients with Active SLE Measured by the Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI): Pooled Data from 2 Phase 3 Studies

Victoria Werth1, Richard Furie2, Eric Morand3, J. Michelle Kahlenberg4, Rubana Kalyani5, Gabriel Abreu6, Lilia Pineda5 and Raj Tummala5, 1University of Pennsylvania and Corporal Michael J. Crescenz Veterans Administration Hospital, Philadelphia, 2Zucker School of Medicine at Hofstra/Northwell, Great Neck, 3Monash University, Melbourne, Australia, 4Division of Rheumatology, University of Michigan, Ann Arbor, MI, 5BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, 6BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden

Meeting: ACR Convergence 2020

Keywords: clinical trial, Cutaneous, Systemic lupus erythematosus (SLE)

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Date: Saturday, November 7, 2020

Session Title: SLE – Treatment (0985–0989)

Session Type: Abstract Session

Session Time: 3:00PM-3:50PM

Background/Purpose: Up to 85% of patients with SLE experience skin disease.1 The Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) is a validated index to measure skin disease severity; activity scores (CLASI-A) range from 0 (mild) to 70 (severe) and include measures for erythema, scale/hypertrophy, mucous membrane lesions, recent hair loss, and nonscarring alopecia. In the phase 3 TULIP-1 and -2 trials of patients with SLE, a greater proportion of patients with CLASI-A ≥10 at baseline achieved ≥50% CLASI-A reduction at Week 12 with anifrolumab compared with placebo.2,3 We further evaluated the effect of anifrolumab on skin-specific SLE disease activity using data pooled from TULIP-1 and -2.

Methods: TULIP-1 and -2 were 52-week, randomized, double-blind, placebo-controlled trials that evaluated the efficacy and safety of anifrolumab (300 mg IV every 4 weeks for 48 weeks) in patients with moderately to severely active SLE despite standard-of-care treatment. TULIP-1 and -2 were analyzed separately using restricted medication rules per the TULIP-2 protocol, and data from both trials were pooled. We compared skin responses over time in patients receiving anifrolumab vs placebo. A CLASI-A response was defined as ≥50% reduction of CLASI-A from baseline for patients with CLASI-A ≥10. Baseline CLASI-A >0 as well as ≥75% reduction were also evaluated. Time to CLASI-A response sustained to Week 52 was evaluated using a Cox proportional hazards model.

Results: In total, 360 patients received anifrolumab and 366 received placebo. At baseline, 95.9% (696/726) of patients had CLASI-A >0, and 27.7% (201/726) had CLASI-A ≥10 (balanced between groups). In the subgroup of patients with baseline CLASI-A ≥10, CLASI-A response (≥50% reduction) was achieved by Week 12 in 46.0% (49/107) of patients receiving anifrolumab vs 24.9% (24/94) receiving placebo (difference 21.0; 95% CI 8.1%, 34.0%; nominal P< 0.001) (Figure 1). Separation between treatment groups was observed as early as Week 8 (difference 14.3; 95% CI 1.8%, 26.9%; nominal P< 0.02) (Figure 1). Time to CLASI-A response sustained to Week 52 favored anifrolumab in TULIP-1 (hazard ratio [HR] 1.91; 95% CI 1.14, 3.27) and TULIP-2 (HR 1.55; 95% CI 0.87, 2.85) (Figure 2). Of the subgroup of patients with baseline CLASI-A >0, a greater number of patients achieved a CLASI-A response (≥50% reduction) by Week 12 in the anifrolumab vs placebo groups in both TULIP-1 and -2 (nominal P< 0.05) (Figure 3); similar effects were observed in the subgroup of patients with baseline CLASI-A ≥10 in both TULIP-1 and -2 (nominal P< 0.05) (Figure 3).

Conclusion: Anifrolumab treatment was associated with rapid and durable improvements in skin-specific SLE disease activity, as assessed by CLASI-A, in subgroups of patients with mild to severe baseline cutaneous disease activity. These findings support the potential of anifrolumab to reduce skin disease activity in patients with moderately to severely active SLE.

 References

  1. Rothfield N. Clin Dermatol. 2006;24:348–62.
  2. Furie RA. Lancet Rheumatol. 2019;1:e208–19.
  3. Morand EF. N Engl J Med. 2020;382:211–21.

 Writing assistance by Rebecca Jones, PhD (JK Associates Inc., a Fishawack Health Company). 

This study was sponsored by AstraZeneca.

Figure 1. Percentage of Patients With CLASI-A ≥10 at Baseline Achieving ≥50% Reduction in CLASI-A From Baseline Over Time in Pooled Data From the TULIP-1 and TULIP-2 Trials

Figure 2. Time to CLASI-A Response (≥50% Reduction From Baseline) Sustained to Week 52 in Patients With CLASI-A ≥10 at Baseline in Data From the TULIP-1 and TULIP-2 Trials

Figure 3. CLASI-A Response at Week 12 by Baseline CLASI-A at 50% and 75% Response Thresholds in Data From the TULIP-1 and TULIP-2 Trials


Disclosure: V. Werth, Corbus Pharmaceuticals, 2, Biogen, 2, 5, Resolve, 2, CSL Behring, 5, Regeneron, 5, Argenx, 5, Viela Bio, 2, 5, Principia, 5, Lilly, 5, Abbvie, 5, AstraZeneca, 2, 5, Amgen, 5, Kyowa Kirin, 5, Glaxo Smith Kline, 5, Cugene, 5, Celgene, 2, 5, Janssen, 2, 5, Pfizer, 2, 5, Gilead, 2, 5, Genentech, 2, 5, Syntimmune, 2, MedImmune, 5, Idera, 5, BMS, 5, Medscape, 5, Nektar, 5, Incyte, 5, EMD Sorona, 5, Crisalis, 5, Octapharma, 5, University of Pennsylvania, 9; R. Furie, AstraZeneca/Medimmune, 2, 5; E. Morand, AstraZeneca, 2, 5, 8, Bristol-Myers Squibb, 2, 5, Eli Lilly, 2, 5, GlaxoSmithKline, 2, 5, Janssen, 2, 5, Merck Serono, 2, 5, Biogen, 5, Neovacs, 5, Sandoz, 5, Novartis, 8; J. Kahlenberg, AstraZeneca, 5, Bristol Myers Squibb, 2, 5, Eli Lilly, 5, Avion Pharma, 5, Celgene, 2; R. Kalyani, AstraZeneca, 1, 3, 4; G. Abreu, AstraZeneca, 3; L. Pineda, AstraZeneca, 3; R. Tummala, AstraZeneca, 3.

To cite this abstract in AMA style:

Werth V, Furie R, Morand E, Kahlenberg J, Kalyani R, Abreu G, Pineda L, Tummala R. Early and Sustained Reduction in Severity of Skin Disease with Anifrolumab Treatment in Patients with Active SLE Measured by the Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI): Pooled Data from 2 Phase 3 Studies [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/early-and-sustained-reduction-in-severity-of-skin-disease-with-anifrolumab-treatment-in-patients-with-active-sle-measured-by-the-cutaneous-lupus-erythematosus-disease-area-and-severity-index-clasi/. Accessed March 3, 2021.
  • Tweet
  • Email
  • Print
Save to PDF

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/early-and-sustained-reduction-in-severity-of-skin-disease-with-anifrolumab-treatment-in-patients-with-active-sle-measured-by-the-cutaneous-lupus-erythematosus-disease-area-and-severity-index-clasi/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.